RIL
NVCT icon

Rothschild Investment LLC’s Nuvectis Pharma NVCT Stock Holding History

Rothschild Investment LLC’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8 Buy
+1
New +$9 ﹤0.01% 3583

Other funds holding NVCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Rothschild Investment LLC's NVCT Position: Q1 2026 in Review

Rothschild Investment LLC opened a new position in Nuvectis Pharma (NVCT) in Q1 2026: 1 share worth $8. The stake represents ﹤0.01% of the portfolio and ranks #3583 among its holdings.

62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

  • Rothschild Investment LLC held 1 share of Nuvectis Pharma worth $8 as of Q1 2026.
  • Nuvectis Pharma was a new Rothschild Investment LLC position in Q1 2026.
  • Nuvectis Pharma made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q1 2026, its #3583 holding.
  • 62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on Rothschild Investment LLC's 13F filing for Q1 2026, filed 7 May 2026.